Supercharged immune cells take aim at tough lymphomas in groundbreaking trial
NCT ID NCT03602157
Summary
This study is testing a new type of personalized cell therapy for adults whose CD30+ lymphomas have come back or not responded to standard treatments. Doctors take a patient's own immune cells (T cells), genetically modify them to better find and attack cancer cells, and then infuse them back into the patient. The main goal of this early-phase trial is to find a safe dose and understand the side effects of these modified cells, either alone or in combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.